Gilead Sciences Inc at Barclays Global Healthcare Conference Transcript
Hi, everybody. Thanks for coming. My name is Emily Field. I am the US large-cap pharma biotech analyst here at Barclays. And we're so fortunate to have Andy Dickinson, who's the CFO of Gilead, joining us today.
So thanks for coming, everybody.
Of course. Yeah, thanks for having us again. We appreciate it.
Questions & Answers
Yeah. So I mean, let's just get into it. I mean, obviously, very important year for Gilead with the Yeztugo launch, but also having done the Arcellx deal. So maybe I'll just like open it up to you and let you talk about how you're looking at the financial picture for Gilead in 2026.
Sure, yeah. I mean, maybe to start overall, we had an extraordinary 2025 in terms of our base business, our clinical
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
